ABO Histo-Blood Groups Influence Makeup of Gut Microbiome
|
By LabMedica International staff writers Posted on 01 Feb 2021 |

Image: False-colored electron microscopic image of Bifidobacterium that are one of the major genera of bacteria that make up the gastrointestinal tract and are associated with variants in the lactase gene locus (Photo courtesy of The Keck Science Department of the Claremont Colleges)
Recent genome-wide association studies yielded inconsistent, underpowered and rarely replicated results such that the role of human host genetics as a contributing factor to microbiome assembly and structure remains uncertain.
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
The intestinal microbiome is implicated as an important modulating factor in multiple inflammatory, neurologic and neoplastic disease. Host genetics, including genes affecting ABO histo-blood groups, may influence the composition of the human gut microbiome.
A large team of scientists at Kiel University (Kiel, Germany) and their colleagues conducted a large genome-wide association study of microbial traits that drew on five cohorts from different regions of Germany that encompassed a total of 8,965 individuals. Following a series of multivariate, univariate abundance, and presence-absence pattern analyses, they uncovered 38 genetic loci associated with the presence of particular bacteria and broad gut microbial community composition.
The team noted an association between variants in the lactase gene locus (LCT) and the genus Bifidobacterium. This association was nominal in four of the five cohorts and stronger in the fifth. They also found an association between a Barnesiella bacterial species and variants in the biliverdin reductase A (BLVRA) gene, which encodes a protein that inhibits toll-like receptor 4 (TLR4) gene expression. The TLR-4 protein is a pattern recognition receptor of the ABO allele.
The scientists investigated ABO histo-blood group associations, including FUT2 secretor status, with microbial features. They found a correlation between non-O blood group and positive secretor status and certain Bacteroides species in four of the five cohorts. Another Bacteroides species, they noted, was also associated with ABO blood status, bolstering the idea that there are histo-blood group-dependent effects on Bacteroides. They further uncovered associations between Faecalibacterium and ABO and between Holdemanella and ABO, as well as an association between FUT2 secretor status and the abundance of Roseburia, independent of ABO type.
Through a Mendelian randomization analysis, the scientists found 19 suggestive microbial effects on host traits, nine of which were tied to Inflammatory Bowel Disease (IBD) or Crohn's disease. One, for instance, suggests that a group of Bacteroides is associated with ABO histo-blood group status and a group of Prevotella appears to protect against Crohn's disease.
Malte Christoph Rühlemann, PhD, the first author of the study, said, “Ultimately, the aim is to identify candidate genes that are investigated in functional studies and that can at one time point be used in a framework of personalized treatment which considers multiple layers of host factors: life history, genetics, the microbiome, and the interaction of them all as target and modulator of treatment success.”
The authors concluded that their findings support the notion that ABO histo-blood group and sector status influences the makeup of the gut microbiome and that they could potentially represent targets for modulating human health and disease. The study was published on January 18, 2021 in the journal Nature Genetics.
Related Links:
Kiel University
Latest Molecular Diagnostics News
- DNA Aptamers Offer New Tool for Easy Alzheimer's Blood Test
- AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
- Blood Test Could Detect Pre-Eclampsia Before Symptoms Appear
- Jumping "DNA Parasites” Linked to Early Tumor Development
- AI-Powered Blood Test Flags Relapse Risk Earlier After Transplant
- AI-Powered Blood Test Detects Early Pancreatic Cancer with More Than 90% Accuracy
- World’s First Portable POC Test Simultaneously Detects Four Common STIs in One Hour
- Simple One-Hour Saliva Test Detects Common Cancers
- Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
- Blood Test Could Spot Common Post-Surgery Condition Early
- New Blood Test Can Help Predict Testicular Cancer Recurrence
- New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
- New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
- Cell-Free DNA Predicts Bloodstream Infections in Children with Leukemia
- Study Uses Blood Samples to Identify Diseases Years Before They Start
- MicroRNA-Based Method Predicts CKD and Cardiovascular Risk
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
DNA Aptamers Offer New Tool for Easy Alzheimer's Blood Test
Alzheimer’s disease is the most common cause of dementia and is marked by progressive loss of nerve cells that begins many years before symptoms become noticeable. Detecting early signs of neurodegeneration... Read more
Jumping "DNA Parasites” Linked to Early Tumor Development
Cancer genomes accumulate complex structural variants that can be difficult to resolve with standard short-read sequencing, obscuring clinically relevant drivers of disease. Transposable elements, particularly... Read more
AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








